Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01847092 · ClinicalTrials.gov registry record · Phase 2

A Study in CKD Patients With Type 2 Diabetes Mellitus and Albuminuria

A Phase 2 study, sponsored by Ardelyx.

Completed
Registry status
Phase 2
Development phase
154
Enrollment target

NCT01847092: Completed Phase 2 study, sponsored by Ardelyx.

NCT01847092 is a Phase 2 study that has completed, run by Ardelyx. The registered enrollment target is 154 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (16% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01847092, a Phase 2 study, has completed, sponsored by Ardelyx.

COMPLETED
Registry status
Phase 2
Development phase
154 participants
Enrollment target

Study Summary

The purpose of this study is to determine if the study drug is safe, tolerable and active in reducing albuminuria in patients with Chronic Kidney Disease with Type 2 Diabetes.

Primary Outcome

The difference between tenapanor and placebo in the change in UACR from baseline to the end of 12 weeks of treatment

Interventions

  • DRUG Placebo
  • DRUG AZD1722

Trial Details

FieldValue
Enrollment Target 154 participants
Start Date 2013-05
Est. Completion 2015-04
Phase Phase 2
Ardelyx

25 total trials

What the finished NCT01847092 record still lists

NCT01847092 is an interventional study that assigns participants to a tested intervention. The registered 154 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (16% higher).

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT01847092 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01847092 about?

NCT01847092 is a clinical study titled "A Study in CKD Patients With Type 2 Diabetes Mellitus and Albuminuria". The purpose of this study is to determine if the study drug is safe, tolerable and active in reducing albuminuria in patients with Chronic Kidney Disease with Type 2 Diabetes.

What is the current status of trial NCT01847092?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 154 participants. The study started on 2013-05. Estimated completion is 2015-04.

What interventions are being tested in trial NCT01847092?

The interventions under investigation include: Placebo (DRUG), AZD1722 (DRUG).

Who is sponsoring clinical trial NCT01847092?

This trial is sponsored by Ardelyx, which has 25 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01847092's enrollment target sits among peer trials

154 448th of 2000 higher than 1,552 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04300998 · 154 participants

    Study of CAR-T Therapy in Older Patients

  • NCT04597372 · 154 participants · Phase 2

    Impact of Tamsulosin on Post-Operative Urinary Retention Following Pelvic Reconstructive Surgery

  • NCT05294042 · 154 participants · NA

    Patient Navigators for Children's Community Mental Health Services in High Poverty Urban Communities

  • NCT05512390 · 154 participants · Phase 1

    A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01847092, the US trial registry maintained by the National Library of Medicine. NCT01847092 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.